LY3437943 NEW

LY3437943(subcutaneous injection; 0.47 mg/kg; Single-dose) is involved in GCGR in vivo and can improve glucose tolerance in ipGTT through GIP or GLP-1 receptors [1]. LY3437943(subcutaneous injection; 10 mL/kg; Cycle once every 3 days; For 21 days) causes substantial weight loss and increased energy expenditure through glucagon receptor activation [1]. LY3437943 is safe and tolerable [1]. Animal model: Male CD-1 mice [1] Dose: 0.47 mg/kg Administration: subcutaneous administration, single result: AUC0-∞, ng*h/mL Cmax,ng/mL Tmax,h t1/2,h CLF,mL/h/kg 41135 41905 1680 12 21 11.22 Animal model: Diet-induced obesity (DIO) male C57/Bl6 mice (24-25 weeks,40-51 g)[1] Dose: 10 mL/kg Administration: Subcutaneous injection (SC) every 3 days for 21 days. Results: Weight loss and blood glucose control improved.